Live Rate
| Open | |
|---|---|
| High | |
| Low | |
| Prev. Close | |
| Lower circuit | |
| Upper circuit | |
| 52w High | |
| 52w Low | |
| P/E Ratio |
Listing Price
| Exchange | Listing Price | Gain/Loss | % |
|---|---|---|---|
| NSE | ₹79.00 | -₹22.00 | -21.78% |
Subscription
Last updated on 16-May-2025 18:32:02
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIB | 141600 | 1719600 | 12.14 |
| NIB | 1222800 | 5244000 | 4.29 |
| RETAIL | 1222800 | 12895200 | 10.55 |
| Total | 2587200 | 19858800 | 7.68 |
| Application Wise Breakup | |
|---|---|
| Category | App. Received |
| QIB | 4 |
| NIB | 889 |
| RETAIL | 10746 |
| Total | 11639 |
| Subscription Demand (in ₹ crore) | |||
|---|---|---|---|
| Category | Offered | Demand | Times |
| QIB | 1.43 | 17.37 | 12.14 |
| NIB | 12.35 | 51.47 | 4.17 |
| RETAIL | 12.35 | 130.24 | 10.55 |
| Total | 26.13 | 199.08 | 7.62 |
| QIB Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹1.6 | @8% ₹1.9 | @9% ₹2.1 | @10% ₹2.4 | @11% ₹2.6 | @12% ₹2.8 |
| HNI Interest Cost Per Share (7 Days) | |||||
|---|---|---|---|---|---|
| @7% ₹0.6 | @8% ₹0.6 | @9% ₹0.7 | @10% ₹0.8 | @11% ₹0.9 | @12% ₹1 |
About
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail (10000 to 2 lakh) | 1 | 1200 | 121200 | 1019 |
IPO Reservation
| Investor Category | Shares Offered | No. of Shares |
|---|---|---|
| Retail | 41.51% | 1222800 |
| HNI | 41.51% | 1222800 |
| Anchor | 7.17% | 211200 |
| QIB | 4.81% | 141600 |
| Market Maker | 5.01% | 147600 |
| Total | 100.00% | 2946000 |
Accretion Pharmaceuticals IPO Details
| Issue Size | 29,46,000 shares (aggregating up to ₹29.75 Cr) |
| Fresh Issue | 29,46,000 shares (aggregating up to ₹29.75 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 81,70,000 shares |
| Share Holding Post Issue | 1,11,16,000 shares |
| Market Maker Portion | 1,47,600 shares |
| Market Maker | Gretex Share Broking |
Key Performance Indicator (KPI)
| KPI | Dec-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| ROE | 38.54% | 72.47% | 2.70% |
| ROCE | 30.14% | 36.73% | 9.87% |
| RONW | 38.54% | 72.47% | 2.70% |
| EPS (basic) | 8.74 | 9.69 | 0.26 |
| P/E Pre IPO | 21.29 | ||
| P/E Post IPO | 16.08 |
Company Financials In Crores
| Period Ended | Dec-24 | Mar-24 | Mar-23 | Mar-22 |
|---|---|---|---|---|
| Assets | 40.0 | 27.1 | 20.6 | 17.7 |
| Revenue | 35.8 | 33.9 | 29.5 | 22.6 |
| Profit After Tax | 5.2 | 3.9 | 0.1 | 0.1 |
| Net Worth | 13.6 | 5.4 | 3.8 | 3.1 |
| Reserves and Surplus | 5.4 | 1.4 | 0.0 | 0.0 |
| Total Borrowing | 13.8 | 13.5 | 8.5 | 7.6 |
Company Overview
Name: Accretion Pharmaceuticals Limited
Founded: 2012
Headquarters: Ahmedabad-Sanand, Gujarat, India
Industry: Pharmaceuticals (Formulations + Contract Manufacturing)
Employee Strength: 83 (including 4 Executive Directors, as of January 2025)
Core Business & Offerings
Product Portfolio:
Tablets/Capsules: Antibiotics, anti-inflammatory, cardiovascular, and gastrointestinal drugs.
Oral Liquids/Syrups: Pediatric, respiratory, and digestive treatments.
External Preparations: Ointments, creams, medicated shampoos, dusting powders.
Ayurvedic/Herbal: Natural wellness products for immunity and digestion.
Services: Contract Manufacturing for third-party brands.
Utilization of Funds
Growth-Oriented Capex (₹73.53M Total: 1+2)
Financial Prudence (₹9.92M Debt Repayment)
Working Capital Dominance (₹146.8M – 64% of Total)
Flexibility (General Corporate Purposes)
Modernization: Upgrading facilities and new machinery will boost production capacity and export readiness (key for 20+ country footprint).
Quality Compliance: Reinforces adherence to ISO/GMP standards, appealing to global clients.
Low Leverage: Minimal debt repayment suggests already lean balance sheet, reducing post-IPO financial risk.
Scalability Focus: Funds will ensure smooth operations amid expansion, especially for contract manufacturing and export orders.
Liquidity Cushion: Mitigates cyclical cash flow challenges in pharma.
Potential uses: R&D, market expansion, or acquisitions
Strength
Experienced Promoters and Management Team – Led by a knowledgeable leadership team with deep industry expertise.
Established Client and Supplier Relationships – Maintains strong, long-term partnerships ensuring business stability.
Weakness
Outstanding Litigation – Ongoing legal proceedings may negatively impact the company’s reputation and financial performance.
Regulatory Compliance – Non-compliance with evolving pharmaceutical regulations could disrupt operations and affect business continuity.
Regulatory Inspections – Adverse findings from inspections or audits by authorities or clients may lead to penalties or reputational harm.
AVOID THIS IF YOU CANT AFFORD RISK
Latest Announcements
| Date | Subject | Attachment Text |
|---|
Financial Results
Lead Manager(s)
Address
29 Xcelon Ind Park 1,
B/h, Intas Pharmaceuticals, Vasna Chacharvad
Sanand,
Phone: +91-97148 82929
Email: compliance@accretionpharma.com
Website: https://accretionpharma.com/